Literature DB >> 26960976

Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients.

Emmanuel Griessinger1, Fernando Anjos-Afonso2, Jacques Vargaftig3, David C Taussig4, François Lassailly3, Thomas Prebet5, Véronique Imbert6, Marielle Nebout6, Norbert Vey5, Christian Chabannon5, Andrew Filby7, Frederic Bollet-Quivogne8, John G Gribben4, Jean-François Peyron6, Dominique Bonnet9.   

Abstract

Acute myeloid leukemia (AML) is sustained by a subpopulation of rare leukemia-initiating cells (LIC) detected in the xenograft assay by their capacity to self-renew and to generate non-LICs in vivo The xenotransplantation model captures functional properties of LICs that have clinical prognostic value. However, the long duration of this in vivo assay has hampered its use as a prognostic tool. Here, we show, using an ex vivo coculture system, that intermediate and poor risk AML patient samples at diagnosis have a 5 to 7 times higher frequency of leukemic long-term culture-initiating cells (L-LTC-IC) compared with the good risk group. We defined a fluorescence dilution factor (FDF) parameter that monitors sample proliferation over 1 week and established a strong correlation of this parameter with the L-LTC-IC frequency. A higher FDF was found for poor prognostic AMLs or for samples capable of engrafting NSG mice compared with good risk AMLs or nonengrafters. Importantly, FDF could classify normal karyotype intermediate risk patients into two groups with a significant difference in their overall survival, thus making this nongenetic and non-in vivo approach a new clinically relevant tool for better diagnosis of AML patients. Cancer Res; 76(8); 2082-6. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 26960976     DOI: 10.1158/0008-5472.CAN-15-2063

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Acute myeloid leukemia including favorable-risk group samples engraft in NSG mice: just be patient.

Authors:  Dominique Bonnet
Journal:  Haematologica       Date:  2017-05       Impact factor: 9.941

2.  NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no.

Authors:  Emmanuel Griessinger; Michael Andreeff
Journal:  Haematologica       Date:  2018-06       Impact factor: 9.941

3.  Leukemia Stem Cells in the Pathogenesis, Progression, and Treatment of Acute Myeloid Leukemia.

Authors:  Kanak Joshi; Lei Zhang; Peter Breslin S J; Jiwang Zhang
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 3.650

4.  The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.

Authors:  Alessandro Di Tullio; Kevin Rouault-Pierre; Ander Abarrategi; Syed Mian; William Grey; John Gribben; Aengus Stewart; Elizabeth Blackwood; Dominique Bonnet
Journal:  Nat Commun       Date:  2017-11-22       Impact factor: 14.919

5.  Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.

Authors:  Hendrik Folkerts; Susan Hilgendorf; Albertus T J Wierenga; Jennifer Jaques; André B Mulder; Paul J Coffer; Jan Jacob Schuringa; Edo Vellenga
Journal:  Cell Death Dis       Date:  2017-07-13       Impact factor: 8.469

6.  Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo.

Authors:  Katherine L B Knorr; Laura E Finn; B Douglas Smith; Allan D Hess; James M Foran; Judith E Karp; Scott H Kaufmann
Journal:  Stem Cells Transl Med       Date:  2016-11-07       Impact factor: 6.940

7.  Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice.

Authors:  Anna M Paczulla; Stephan Dirnhofer; Martina Konantz; Michael Medinger; Helmut R Salih; Kathrin Rothfelder; Dimitrios A Tsakiris; Jakob R Passweg; Pontus Lundberg; Claudia Lengerke
Journal:  Haematologica       Date:  2017-02-09       Impact factor: 9.941

8.  Acute myeloid leukemia xenograft success prediction: Saving time.

Authors:  Emmanuel Griessinger; Jacques Vargaftig; Stuart Horswell; David C Taussig; John Gribben; Dominique Bonnet
Journal:  Exp Hematol       Date:  2017-12-15       Impact factor: 3.084

9.  Dexamethasone in hyperleukocytic acute myeloid leukemia.

Authors:  Sarah Bertoli; Muriel Picard; Emilie Bérard; Emmanuel Griessinger; Clément Larrue; Pierre Luc Mouchel; François Vergez; Suzanne Tavitian; Edwige Yon; Jean Ruiz; Eric Delabesse; Isabelle Luquet; Laetitia Karine Linares; Estelle Saland; Martin Carroll; Gwenn Danet-Desnoyers; Audrey Sarry; Françoise Huguet; Jean Emmanuel Sarry; Christian Récher
Journal:  Haematologica       Date:  2018-03-08       Impact factor: 9.941

10.  Chromatin accessibility promotes hematopoietic and leukemia stem cell activity.

Authors:  Lucia Cabal-Hierro; Peter van Galen; Miguel A Prado; Kelly J Higby; Katsuhiro Togami; Cody T Mowery; Joao A Paulo; Yingtian Xie; Paloma Cejas; Takashi Furusawa; Michael Bustin; Henry W Long; David B Sykes; Steven P Gygi; Daniel Finley; Bradley E Bernstein; Andrew A Lane
Journal:  Nat Commun       Date:  2020-03-16       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.